Äquivalenzstudien und Nicht-Unterlegenheitsstudien

Schlüsselwörter

Äquivalenz - Nicht-Unterlegenheit - Klinisch relevante Differenz - Konfidenzintervall

Key words

Equivalence - Non-inferiority - Clinically relevant difference - Confidence interval

Literatur

• 1 Altman D G, Bland J M. Absence of evidence is not evidence of absence.  BMJ. 1995;  311 485
• 2 Bender R, Lange S. Was ist der p-Wert?.  Dtsch Med Wochenschr. 2007;  132 e15-e16
• 3 Blackwelder W C. „Proving the null hypothesis” in clinical trials.  Control Clin Trials. 1982;  3 345-353
• 4 CPMP . Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products. CPMP Working Party on Efficacy of Medicinal Products Note for Guidance III/3630/92-EN.  Stat Med. 1995;  14 1659-1682
• 5 CPMP .Guideline on the choice of the non-inferiority margin. CPMP/EWP/2158/99 2005. http://www.emea.eu.int/pdfs/human/ewp/215899en.pdf (letzter Zugriff am 25.9.2005) 2005
• 6 CPMP .Points to consider on switching between superiority and non-inferiority. CPMP/EWP/482/99 2000. http://www.emea.eu.int/pdfs/human/ewp/048299en.pdf (letzter Zugriff am 25.9.2005) 2005
• 7 Garbe E, Röhmel J, Gundert-Remy U. Clinical and statistical issues in therapeutic equivalence trials.  Eur J Clin Pharmacol. 1993;  45 1-7
• 8 Hampton J R. Mega-trials and equivalence trials: experience from the INJECT study.  Eur Heart J. 1996;  17 (Suppl E) 28-34
• 9 Hampton J R. Alternatives to mega-trials in cardiovascular disease.  Cardiovasc Drugs Ther. 1997;  10 759-765
• 10 Hartung J, Cottrell J E, Giffen J P. Absence of evidence is not evidence of absence.  Anesthesiology. 1983;  58 298-300
• 11 Henry D, Hill S. Comparing treatments: Comparison should be against active treatments rather than placebos.  BMJ. 1995;  310 1279
• 12 ICH Harmonised Tripartite Guideline . Statistical principles for clinical trials (E9).  Stat Med. 1999;  18 1905-1942
• 13 ICH Harmonised Tripartite Guideline .Choice of control group and related issues in clinical trials (E10). http://www.emea.eu.int/pdfs/human/ich/036496en.pdf (letzter Zugriff am 25.9.2005) 2000
• 14 International Joint Efficacy Comparison of Thrombolytics . Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence.  Lancet. 1995;  346 329-335
• 15 Jones B, Jarvis P, Lewis J A, Ebbutt A F. Trials to assess equivalence: the importance of rigorous methods.  BMJ. 1996;  313 36-39
• 16 Lange S, Bender R. Was ist ein Signifikanztest?.  Dtsch Med Wochenschr. 2007;  132 e19-e21
• 17 Lange S, Windeler J. Das Konzept der therapeutischen Äquivalenz.  Med Klin. 1997;  92 215-220
• 18 Makuch R, Johnson M. Issues in planning and interpreting active control equivalence studies.  J Clin Epidemiol. 1989;  42 503-511
• 19 Makuch R, Pledger G, Hall D B, Johnson M F, Herson J, Hsu J -P. Active Control Equivalence Studies. In: Peace KE; Hrsg. Statistical issues in drug research and development New York: Marcel Dekker, 1990: 225-262
• 20 Modell W, Houde R W. Factors influencing clinical evaluation of drugs. With special reference to the double-blind technique.  JAMA. 1958;  167 2190-2199
• 21 Senn S J. Inherent difficulties with active control equivalence studies.  Stat Med. 1993;  12 2367-2375
• 22 Wellek S. Planung und statistische Auswertung von Äquivalenzstudien im Rahmen der klassischen Theorie des Hypothesentestens. In: Michaelis J, Hommel G, Wellek S; Hrsg. Europäische Perspektiven der Medizinischen Informatik, Biometrie und Epidemiologie München: MMV, Medizin-Verlag 1993: 143-147
• 23 Wellek S. Testing Statistical Hypotheses of Equivalence. Boca Raton: Chapman & Hall/CRC 2003
• 24 Windeler J, Trampisch H J. Empfehlung zur Durchführung von Studien zur therapeutischen Äquivalenz.  Inform Biom Epidem Med Biol. 1995;  26 350-355
• 25 World Medical Association .Declaration of Helsinki - Ethical principles for medical research involving human subjects. Revision of the 52nd WMA General Assembly, Edinburgh, Scotland http://www.wma.net/e/policy/b3.htm (letzter Zugriff am 25.9.2005) 2000